Novartis has begun construction on its new 46,000ft² radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking the latest step in its $23bn investment in US manufacturing and research.
Angelini Pharma has signed a definitive agreement to purchase Catalyst Pharmaceuticals for a total equity value of nearly €3.5bn ($4.1bn), marking its entrance into the US market and consolidating its focus on brain health and rare diseases.
Daiichi Sankyo has entered a collaboration with France-based Waiv, which aims to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) programme.
Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics for the development of ORKA-001 using Hypercon Technology.
Citius Oncology has secured up to $36.5m in a combination of debt and equity financing to accelerate the commercialisation of Lymphir (denileukin diftitox-cxdl), a recombinant fusion protein immune therapy.
Merck & Co (MSD) has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).
Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies to wider patient groups.
LEO Pharma has signed a definitive agreement for the acquisition of Replay, a gene therapy company that develops treatments for rare genetic dermatological conditions.
Ray Therapeutics has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).
Arcera Life Sciences and Fosun Pharma have signed a memorandum of understanding (MoU) for a strategic long-term collaboration in licensing, technology, and neuroscience innovation in the global life sciences industry.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.